60

Tianjin Pharmaceutical Da Ren Tang Group Corp LtdSHG 600329 Stock Report

Last reporting period 30 Sep, 2023

Updated 21 Oct, 2024

Last price

Market cap $B

3.532

Middle

Exchange

XSHG - Shanghai Stock Exchange

600329.SS Stock Analysis

60

Neutral

Based on Eyestock quantitative analysis, 600329.SS`s fundamental data and valuation indicate an investment grade of Neutral at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

56/100

Moderate score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

-16.3 %

Overvalued

Market cap $B

3.532

Dividend yield

3.83 %

Shares outstanding

768.87 B

Tianjin Zhongxin Pharmaceutical Group Co., Ltd. engages in the manufacture, operation and scientific research of green traditional Chinese medicine. The company is headquartered in Tianjin, Tianjin and currently employs 4,650 full-time employees. The company went IPO on 2001-06-06. The firm's businesses cover the whole industry chain of traditional Chinese medicine, including the cultivation of Chinese medicinal materials, trade of Chinese medicinal materials, research and development (R&D), production and sales of Chinese patent medicines, production and sales of Chinese herbal decoction pieces, pharmaceutical commercial logistics, pharmaceutical retailing, chemical raw materials and preparations, biomedicine and many other fields. The firm's products include cardiovascular and cerebrovascular medicines, respiratory medicines, spleen and stomach medicines, cold medicines, oncology medicines, gynecological medicines, pediatric medicines and other other product groups.

View Section: Eyestock Rating